The lasting impact of the Inflation Reduction Act: a Q&A with Jon Koch, CEO, Fishawack Health
Jon Koch, CEO, Fishawack Health, shares his perspective on the implications of the US Inflation Reduction Act (IRA) for manufacturers across the globe.
On 16 August 2022, President Biden signed the IRA into law, marking one of the most significant reformations of the US healthcare system since the Affordable Care Act.
The policy is designed to make innovative medicines more affordable, driving greater access for patients. While this is positive for patients and manufacturers, the implications are far-reaching and the policy will have a direct impact on revenue for biopharmaceutical companies. For example, the IRA gives greater negotiating power to Medicare, calls for a redesign of Medicare Part D, and requires manufacturers to pay rebates if Medicare prices rise above inflation.
In this update, Jon Koch provides his perspective on the policy, including:
the impact for established pharmaceutical and emerging biotechnology companies
how the IRA could transform the way therapies are commercialized
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.